Susceptibility genes for Kawasaki disease: toward implementation of personalized medicine

Akira Hata1, Yoshihiro Onouchi

  • 1Department of Public Health, Graduate School of Medicine, Chiba University, Chiba, Japan. ahata@faculty.chiba-u.jp

Journal of Human Genetics
|January 23, 2009
PubMed

Insights

Kawasaki disease (KD) is a vasculitis affecting young children. Genetic studies identified inositol 1,4,5-trisphosphate 3-kinase C (ITPKC) as a predisposing gene, paving the way for personalized medicine.

Area of Science:

  • Pediatric Rheumatology
  • Immunology
  • Genetics

Background:

  • Kawasaki disease (KD) is an acute systemic vasculitis primarily affecting children under five.
  • Untreated KD leads to coronary artery lesions in 20-25% of cases, a leading cause of acquired heart disease in children.
  • Extensive epidemiological data from Japan since 1970 reveal a strong genetic influence on KD susceptibility.

Purpose of the Study:

  • To review cumulative knowledge on Kawasaki disease.
  • To outline a hypothesis on the role of ITPKC in KD susceptibility.
  • To describe efforts toward personalized medicine for KD.

Main Methods:

  • Genome-wide linkage study using affected sibling pair data from Japan.
  • Analysis of susceptibility loci, focusing on chromosome 19.
  • Identification of the predisposing gene, inositol 1,4,5-trisphosphate 3-kinase C (ITPKC).

Main Results:

  • Identification of several susceptibility loci for Kawasaki disease.
  • Pinpointing ITPKC as a predisposing gene for KD.
  • Establishing a genetic basis for KD susceptibility.

Conclusions:

  • ITPKC plays a significant role in Kawasaki disease susceptibility.
  • Understanding the genetic underpinnings of KD is crucial for developing targeted therapies.
  • Research is progressing towards personalized medicine approaches for Kawasaki disease management.

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
53
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
65
Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
74
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
60
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
16.0K